1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Pulmonary Hypertension - Global Market Research 2015-2019

Pulmonary Hypertension - Global Market Research 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 65 pages

About pulmonary hypertension
Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.

Technavio's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.

Technavio's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key Vendors
- Actelion
- Bayer
- GlaxoSmithKline
- United Therapeutics

Other prominent vendors
- Aires Pharmaceuticals
- Arena Pharmaceuticals
- Bial
- DEKA
- Dong-A ST
- Gilead
- Merck
- Northern Therapeutics
- Novartis
- Pfizer
- PhaseBio

Key market driver
- Growing incidence of pulmonary hypertension
- For a full, detailed list, view our report

Key market challenge
- Patent expiry
- For a full, detailed list, view our report

Key market trend
- Increased focus on combination therapies
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Pulmonary Hypertension - Global Market Research 2015-2019
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Pipeline portfolio
Key information of pipeline candidates
PART 07: Market segmentation by type of formulation
Oral
Injection
Inhalation
PART 08: Market segmentation by mechanism of action
Endothelin receptor antagonist
Prostacyclin analogs
Phosphodiesterase inhibitors
Soluble guanylate cyclase stimulators
PART 09: Geographical segmentation
PART 10: Market drivers
Increase in incidence of pulmonary hypertension
Patient assistance programs
New disease-modifying therapies
Unmet medical needs
PART 11: Impact of drivers
PART 12: Market challenges
Patent expiry
Poor patient compliance
Intense competition among vendors
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on combination therapies
Increase in awareness of hypertension
Strategic alliances
PART 15: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors
PART 16: Key vendor analysis
Actelion Pharmaceuticals
Bayer HealthCare
GSK
United Therapeutics
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global pulmonary hypertension market: 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline portfolio
Exhibit 05: Market segmentation by type of formulation
Exhibit 06: Market segmentation by type of formulation 2014
Exhibit 07: Market segmentation by mechanism of action
Exhibit 08: Market segmentation by mechanism of action 2014
Exhibit 09: Market segmentation by region 2014
Exhibit 10: Impact of drivers
Exhibit 11: Revatio sales in the US 2011-2014 ($ millions)
Exhibit 12: Impact of drivers and challenges
Exhibit 13: Actelion Pharmaceuticals : Key takeaways
Exhibit 14: Tracleer: Global sales 2011-2014 ($ billions)
Exhibit 15: Opsumit: Global sales 2013-2015 H1 ($ millions)
Exhibit 16: Ventavis: Global sales 2011-2014 ($ millions)
Exhibit 17: Veletri: Global sales 2011-2014 ($ millions)
Exhibit 18: United Therapeutics: Key takeaways
Exhibit 19: Remodulin: Global sales 2011-2014 ($ millions)
Exhibit 20: Tyvaso: Global sales 2011-2014 ($ millions)
Exhibit 21: Adcirca: Global sales 2011-2014 ($ millions)
Exhibit 22: Orenitram: Global sales 2014-2015 H2 ($ millions)
Exhibit 23: GlaxoSmithKline: Key takeaways
Exhibit 24: Flolan: Global sales 2012-2013 ($ millions)
Exhibit 25: Bayer: Key takeaways
Exhibit 26: Adempas: Global sales 2013-2014 ($ millions)
Exhibit 27: Actelion Pharmaceuticals: Product segmentation
Exhibit 28: Actelion Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 29: Actelion Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 30: Actelion Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 31: United Therapeutics: Product segmentation by revenue 2014
Exhibit 32: United Therapeutics: Product segmentation by revenue 2014 ($ millions)
Exhibit 33: United Therapeutics: Geographical segmentation by revenue 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hypertension Forecast in 12 Major Markets 2016-2026

Epiomic Epidemiology Series: Hypertension Forecast in 12 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • November 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hypertension in 12 Major Markets Hypertension (high blood pressure) is a common condition in which the force of the blood against the ...

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Pulmonary ...

Global Hypertension Management Devices Market Research Report 2016

Global Hypertension Management Devices Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Hypertension Management Devices Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Hypertension Management Devices industry, ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.